近年来，国内药企正加速出海，其以 “临床价值 + 全球合规” 为核心，已深度融入全球主流市场。据悉，2026 年初，国产药在 FDA 获批与受理就已十分密集。如1月12日，润生药业自主研发的核心产品“沙美特罗替卡松吸入粉雾剂”(药品申请号：ANDA 214464)，正式获得美国食品药品监督管理局(FDA)批准上市。据悉，该产品已于2025年在国内市场申报上市，目前处于国家药监局及国家药品审评中心...
Source Link近年来，国内药企正加速出海，其以 “临床价值 + 全球合规” 为核心，已深度融入全球主流市场。据悉，2026 年初，国产药在 FDA 获批与受理就已十分密集。如1月12日，润生药业自主研发的核心产品“沙美特罗替卡松吸入粉雾剂”(药品申请号：ANDA 214464)，正式获得美国食品药品监督管理局(FDA)批准上市。据悉，该产品已于2025年在国内市场申报上市，目前处于国家药监局及国家药品审评中心...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.